Ulcer recurrence in high-risk patients receiving nonsteroidal anti-inflammatory drugs plus low-dose aspirin: Results of a post hoc subanalysis

Clinical Therapeutics

Volumn 26, Issue 10, 2004, Pages 1637-1643

  Goldstein, Jay L ^a   Huang, Bidan ^b   Amer, Fouad ^c   Christopoulos, Nikos G ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b ABBOTT LABORATORIES   (United States)

^c TAP PHARMACEUTICAL PRODUCTS INC   (United States)

Author keywords

gastroprotection; lansoprazole; misoprostol; NSAIDs; proton pump inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; DICLOFENAC; IBUPROFEN; LANSOPRAZOLE; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DUODENUM ULCER; DYSPEPSIA; FEMALE; GASTROINTESTINAL ENDOSCOPY; HEART PALPITATION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT PEPTIC ULCER; RISK ASSESSMENT; STOMACH ULCER;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; ASPIRIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DUODENAL ULCER; FEMALE; HUMANS; MALE; MIDDLE AGED; MISOPROSTOL; OMEPRAZOLE; PEPTIC ULCER HEMORRHAGE; PROSPECTIVE STUDIES; PROTON PUMPS; RECURRENCE; RISK FACTORS; STOMACH ULCER; TREATMENT OUTCOME;

EID: 10444250250     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2004.10.002     Document Type: Article

References (30)

1. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient Gastroenterology 120 2001 594 606
2. Ofman J.J., MacLean C.H., and Straus W.L. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiiflammatory drugs J Rheumatol 29 2002 804 812
3. Gabriel S.E., Jaakkimainen L., and Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A metaanalysis Ann intern Med 15 1991 787 796
4. Hernandez-Diaz S., and Rodriguez L.A. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: An overview of epidemiologie studies published in the 1990s Arch Intern Med 160 2000 2093 2099
5. [published correction appears in N Engl J Med. 1999;341: 548] Wolfe M.M., Lichtenstein D.R., and Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs N Engl J Med 340 1999 1888 1899
6. Singh G., and Rosen Ramey D. NSAID induced gastrointestinal complications: The ARAMIS perspective--1997. Arthritis, Rheumatism, and Aging Medical Information System J Rheumatol Suppl 51 1998 8 16
7. Langman M.J., Jensen D.M., and Watson D.J. Adverse upper gastrointestinal effects of rofecoxib compared with NSAADs JAMA 282 1999 1929 1933
8. Simon L.S., Weaver A.L., and Graham D.Y. Antiinflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial JAMA 282 1999 1921 1928
9. Spiegel B.M., Targownik L., Dulai G.S., and Gralnek I.M. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis Ann Intern Med 138 2003 795 806
10. El-Serag H.B., Graham D.Y., Richardson P., and Inadomi J.M. Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs: The use of a nomogram in cost-effectiveness analysis Arch Intern Med 162 2002 2105 2110
11. Talley N.J., Evans J.M., and Fleming K.C. Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly Dig Dis Sci 40 1995 1345 1350
12. Curhan G.C., Bullock A.J., and Hankinson S.E. Frequency of use of acetaminophen, nonsteroidal antiinflammatory drugs, and aspirin in US women Pharmacoepidemiol Drug Saf 11 2002 687 693
13. Jackson E.A., Sivasubramian R., and Spencer F.A. Changes over time in the use of aspirin in patients hospitalized with acute myocardial infarction (1975 to 1997): A population-based perspective Am Heart J 144 2002 259 268
14. Brown J.B., Delea T.E., and Nichols G.A. Use of oral antithrombotic agents among health maintenance organization members with atherosclerotic cardiovascular disease Arch Intern Med 162 2002 193 199
15. Weil J., Colin-Jones D., and Langman M. Prophylactic aspirin and risk of peptic ulcer bleeding BMJ 310 1995 827 830
16. Derry S., and Loke Y.K. Risk of gastrointestinal haemorrhage with long term use of aspirin: Meta-analysis BMJ 321 2000 1183 1187
17. Garcia Rodriguez L.A., Hernandez-Diaz S., and de Abajo F.J. Association between aspirin and upper gastrointestinal complications: Systematic review of epidemiologic studies Br J Clin Pharmacol 52 2001 563 571
18. Sorensen H.T., Mellemkjaer L., and Blot W.J. Risk of upper gastrointestinal bleeding associated with use of lowdose aspirin Am J Gasiroenterol 95 2000 2218 2224
19. Silverstein F.E., Faich G., and Goldstein J.L. Gastrointestinal toxicity with celecoxib vs nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: Arandomized controlled trial. Celecoxib Long-Term Arthritis Safety Study JAMA 284 2000 1247 1255
20. Lai K.C., Lam S.K., and Chu K.M. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use N Engl J Med 346 2002 2033 2038
21. Chan F.K., Chung S.C., and Suen B.Y. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen N Engl J Med 344 2001 967 973
22. Hawkey C.J., Karrasch J.A., Szczepanski L. Omeprazole Versus Misoprostol for NSAID-Induced Ulcer Management (OMNIUM) Study Group Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs N Engl J Med 338 1998 727 734
23. Yeomans N.D., Tulassay Z., and Juhasz L. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: RanitidineVersus Omeprazole for NSAID-Associated Ulcer Treatment (ASTRONAUT) Study Group N Engl J Med 338 1998 719 726
24. Graham D.Y., Agrawal N.M., Campbell D.R. NSAID-Associated Gastric Ulcer Prevention Study Group Ulcer prevention in long-term users of nonste roidal anti-inflammatory drugs: Results of a doubleblind, randomized, multicenter, active- and placebocontrolled study of misoprostol vs lansoprazole Arch Intern Med 162 2002 169 175
25. Agrawal N.M., Campbell D.R., Safdi M.A. NSAID-Associated Gastric Ulcer Study Group Superiority of lansoprazole vs ranitidine in healing nonste roidal anti-inflammatory drug-associated gastric ulcers: Results of a double-blind,randomized, multicenter study Arch Intern Med 160 2000 1455 1461
26. Abstract Goldstein J.L., Guang B., Collis C.M., and Lukasik N.L. PPI based healing of NSAID associated ulcers in patients continuing NSAADs Am J Gastroenterol 95 2000 2452
27. Bombardier C., Laine L., Reicin A. VIGOR Study Group Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis N Engl J Med 343 2000 1520 1528
28. Abstract G0759 Goldstein J.L., Agrawal N.M., and Silverstein F. Influence of H. pylori (Hp) infection and/or low dose aspirin (AASA) on gastroduodenal ulceration in patients treated with placebo, celecoxibor NSAADs Gastroenterology 116 1999 A174
29. Abstract Goldstein J.L., Kent J., and Shu V. Valdecoxib is less ulcerogenic than conventional NSAIDs in osteoarthritis (OA) and rheumatoid arthritis (RA) patients with high risk of peptic ulcer disease Gastroenterology 122 Suppl 1 2002 A345
30. (Suppl) Goldstein J.L., Gibofsky A., and Fort J.G. Incidence of endoscopic gastroduodenal ulcers in subjects on 325 mg qd of aspirin for cardiovascular prophylaxis with placebo, a COX-2 specificinhibitor or a nonspecific NSAID: Results from a randomized, doubleblind, controlled trial Abstract Arthritis Rheum 48 2002 B14